Long-Term Safety Profile of Secukinumab AnalysisRheumnow PodcastLong-Term Safety Profile of Secukinumab Analysis of Malignancies Up to 5 Years of Exposure Across Indications Sponsored by Novartis Medical Affairs...4 years agoLong-Term Safety Profile of Secukinumab AnalysisRheumnow Podcast0:00 / 0:00Read the original at soundcloud.comUse this feed in your RSS readerCopy the publisher’s public feed URL, or build an OPML reading list for another reader.Copy RSS URL Open RSS feed · Find feeds & export OPMLKeep up with this sourceFollow this sourceKeep this source in your dashboard and return to its latest articles. Email alerts are managed separately in Settings.FetchFeeds groups articles by feed so you can follow sources, compare coverage, and save stories for later.Back to all articles from Rheumnow PodcastMore from this feedChoose another story from Rheumnow Podcast.RheumNow Live Is Coming To Town (3.11.2022)QD Clinics - Lessons from the clinic (QD 170-173)Consequences Of TNF InhibitionQD Clinics - Lessons from the clinic (QD 174-177)Lupus Worries (3 - 25 - 22)RheumNow Podcast – PsA All the Way – All April (4.1.2022)QD Clinics - Lessons from the clinic (QD 178-182)TNR- What Patients Say About PsA
